Denosumab was approved by the FDA nearly 15 years ago, and anti-RANKL treatment has improved clinical outcomes in patients with a wide variety of skeletal conditions (giant cell tumor of the bone, bone metastases, osteoporosis, and multiple myeloma) [31]. The gene discussed is TNFSF11; the disease is bone giant cell tumor.